• Home
  • Science
    • ImmunoBody®
    • Moditope®
    • Glymab®
    • Publications
  • Pipeline
  • News
  • Investors
    • Share Info
    • Financial Info
    • Documents & Presentations
    • Corporate Governance
  • Contact Us
    • Find a trial
    • Become an Investigator

Notice of Results

by chantal | Sep 4, 2025 | Latest News, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Scancell reports Strong Phase 2 Data on iSCIB1+ in Advanced Melanoma

by chantal | Jul 24, 2025 | Immunobody, Investor Presentations, iSCIB1+

Successful SCOPE outcome and iSCIB1+ selection

by chantal | Jul 22, 2025 | iSCIB1+, SCIB1, Trinity Delta Reports

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Active Immunotherapy for a Cancer-Free Future

by chantal | Jul 22, 2025 | Immunobody, Investor Presentations, iSCIB1+, SCIB1

Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody® iSCIB1+

by chantal | Jul 22, 2025 | Latest News, News

« Older Entries
Next Entries »

Recent Posts

  • Notice of Annual General Meeting November 2026
  • Result of General Meeting
  • Form F-4 (October 2026)
  • Preliminary Results for the year ended 30 April 2026
  • Atlantic crossing transforms outlook

Recent Comments

No comments to show.

Scancell is focused on developing novel immunotherapies for the treatment of cancer and was founded in 1996 based on research led by Professor Lindy Durrant at the University of Nottingham in the UK.

  • Follow
  • Follow

Science
Our Pipeline
News
Contact Us
Find a Trial
Become an Investigator

ACTIVE IMMUNOTHERAPY

ImmunoBody®
Moditope®

ANTIBODIES

GlyMab®
AvidiMab®

Investors
Company Profile
Advisors
Corporate Governance
Documents & Presentations
Share Information
Financial Information

Copyright © 2026 Scancell | Website Designed & Developed by Identity Creative | Privacy & Cookie Policy